Annual Biomarkers Congress

Osaka, Japan   September 20-21, 2018

Biomarkers Congress 2018

Theme: Biomarkers: a new era of detection and clinical exploration

Meetings International proudly announces the International Conference and Expo on Biomarkers and Genomic Medicine” which will be held during September 20-21, 2018 at Osaka, Japan. The theme of the conference is Biomarkers: Innovation and Implementation of Genomics Research”. Meetings International provides a Global Platform for Medical, Healthcare Professionals Bioinformatics, Genomicist and Biotech Professionals to Exchange Ideas, Knowledge and Networking at its International Conferences. The global Biomarkers industry and market analysis, estimated at for 2007 was $3.6 billion and is expected to grow at a 6.3% CAGR (Compounded Annual Growth Rate) to reach up to $6.3 billion by 2018.

Biomarkers Meeting 2018 aims to bring together researchers, pharmacists, medicine specialist and delegates from medicine, bioinformatics, genomicist and pharmacy fields. Meet Inspiring Speakers and Experts.  The theme of the conference isBiomarkers: Innovation and Implementation of Genomics Research”. Biomarkers Meeting 2018 mainly focusses on the universities, institutes, research centers and major societies along with companies which hold a big market in laboratory technologies. Target audience involves students, faculties, researchers, scientists, dean, directors, and CEOs of the companies.

Attend to gain an unmatched experience in the Biomarkers and Genomics medicine field. In addition to the many scientific sessions and take-home case study examples, you will leave this event with many other novel development strategies from some of our workshops and symposiums. Engage in dynamic conversation with your industry peers at our multiple networking sessions, and takeaway novel development and commercialization strategies, which could speed up a time to market and save your organization millions. We hope you will join us in Japan next October to enhance your research capabilities, and increase the time to market on therapeutics.

  Meetings International proudly announces the “International Conference and Expo on Biomarkers and Genomic Medicine” which will be held during September 20-21, 2018at Osaka, Japan. The theme of the conference is “Biomarkers: Innovation and Implementation of Genomics Research”. Meetings International provides a Global Platform for Medical, Healthcare Professionals Bioinformatics, Chemistry and Biotech Professionals to Exchange Ideas and knowledge.

Track 1: Biomarkers 

  A Biomarkers is an appropriate that can be equitably measured and assess as an indicator of a physiological as well as a pathological progress or pharmacological response to a therapeutic intervention. Classical biomarkers are quantitative alteration in blood pressure; blood lactate levels consecutive exercises, and blood glucose in diabetes mellitus. A biomarker, or bio indicator, for the most part alludes to a quantifiable pointer of some organic state or condition. The term is additionally infrequently used to allude to a substance the nearness of which demonstrates the presence of a living being. Environmental Assessment also carried out in the natural or synthetic form as biomonitoring. Encourage, life structures, life events for Interim analysis. Biomarkers are regularly measured and assessed to look at ordinary natural procedures, pathogenic procedures, or pharmacologic reactions to a restorative mediation.

Related Societies and Associations: Alzheimer's Association, American Brain Tumor Association, American Society of Clinical Oncology, Association for Molecular, Pathology, Cancer Research Society, Cancer Research UK,

Track 2: Clinical application for biomarkers

Clinical medicine as Biomarkers has been used for decades. A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacologic responses to a therapeutic intervention Any specific molecular conversion of a cell on DNA, RNA, metabolite, or protein level can be referred to as Molecular biomarkers .The fuse of biomarker in clinical trials for different illness conditions will advance a certain indicative and remedial approach using even the medicinal gadgets to recognize clinical biomarkers. Right now, this is the trending business.

Related Societies and Associations: German Society for Oncological Pharmacy, National Cancer Institute at the National Institutes of Health, The ALS Association, The British Association for Cancer Research, The Canadian Cancer Society, The International Society Of Oncology and Biomarkers, The Swedish Cancer Society

Track 3: Biomarkers in oncology

    The indicative process of the presence of cancer in the body is referred as cancer biomarkers. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. There are different of cancer where biomarkers have it application such as lung, Melanoma, breast, Colorectal, Pancreas and many more. Biochemically, cancer biomarkers can be DNA (germline or somatic), RNA, proteins, peptides, hormones, metabolites, and even biological processes such as apoptosis, angiogenesis or proliferation. There are three major types of cancer biomarkers based on their clinical use: prognostic, predictive, and pharmacodynamic markers

Related Societies and Associations: European Society of Human Genetics, European Genetics Foundation, European Cytogeneticist Association, European Society of Gene Therapy, Clinical Molecular Genetics Society, Association of Genetic Nurses and Counsellors,

Track 4: Biomarkers and Diseases

A biomarker is a distinctive that can be equitably measured as an indicator of commonly biological processes, pathogenic processes or a pharmacological response to a therapeutic intervention. Biomarkers can be used for many purposes including disease diagnosis and prognosis, prediction and assessment of treatment response. Also, Biomarkers are used as an indicator of a biological factor that represents either a subclinical manifestation, stage of the disorder, or a surrogate manifestation of the disease. The potential uses of this class of biomarkers include, firstly as identification of individuals destined to become affected or who are in the “preclinical” stages of the illness, secondly, reduction in disease heterogeneity in clinical trials or epidemiologic studies, third, reflection of the natural history of disease encompassing the phases of induction, latency and detection, and finally, target for a clinical trial.

Related Societies and Associations: Association of Clinical Cytogeneticists, British Society for Human Genetics, Clinical Genetics Society, Clinical Molecular Genetics Society, Genetics Society, Human Genetics Commission, The United Kingdom Genetical Society,

Track 5: Biomarkers in diseases: methods discover and application

 Those putative biomarkers for Disease diagnosis and prognosis the complexity of structure and function of protein biomarkers and lack of high sensitivity, specificity, and reproducibility. The Food and Drug Administration has approved few biomarkers due to its advanced technology. The practical application of each protein separation or identification technique is analyzed using specific examples, Including four major application of immunology as ELISA, FACS, Western Blot and Immunoprecipitation. Mass spectrometers are unique which can directly analyze any biological molecule likely to be influenced to ionization. The biological studies of human metabolites and proteins using recent mass spectrometry technology (metabolomics and proteomics, respectively) have been ongoing for over a decade.      

Related Societies and Associations: Austrian Society for Human Genetics, Belgian Society for Human Genetics, Czech Society of Medical Genetics, Danish Society of Medical Genetics, Dutch Association of Clinical Genetics, Finnish Society of Medical Genetics, French Society of Human Genetics

Track 6: Development of Biomarkers

 The major uses of biomarkers in clinical investigation are in the form of clinical trials and monitoring. The entire spectrum of disease from the earliest indication to the terminal stages resonate biomarkers. Field studies of biomarkers is generally done on the environmental assessment based on aquatic contamination by seeing the aqua life or by understanding the normal habitat change of different organism .biomarkers also shows the best relationships between its response when compared to the health /ecological effect. It provides variety of human and animal materials principally through immuno-assays and quantitative PCR can be analytically determined at Biomarker Laboratory.

Related Societies and Associations: American Society of Human Genetics, National Society of Genetic Counselors, American College of Medical Genetics, American Board of Genetic Counseling, American Board of Medical Genetics,

Track 7: Imaging Biomarkers and Instrumentation.

A biologic aspect or biomarker detectable in an image is being termed as imaging biomarkers. The most valuable sources of data in evidence-based medicine are to be known as clinical trials. As Instrumentation, it involves different tools and techniques such as, CT, MRI, PET and ultrasonography biomarkers which are broadly used in cancer research and drug development. As medical imaging has made advanced technologies, older corresponding techniques have been repeatedly exchanged with newer digital methods of image acquisition, processing, archiving, and display. This evolution has occurred in parallel with advancements in our understanding of the molecular underpinnings of disease and the rise of a more statistical and evidence-based approach to diagnosis and treatment.

Related Societies and Associations: Nation Coalition for Health Education in Genetics, International Society of Nurses in Genetics, Council of Regional Networks, Association of Genetic Technologists, Genetic Society of America

Track 8:  Biomarkers in toxicology

To all aspects of biomarkers that relate to chemical exposure and their effects on biological systems is a commonly referred as biomarkers in toxicology. Both vertebrate and non-vertebrate species models for toxicological testing and development of biomarkers are being used for recent research. The study of the harmful effects of various chemical, biological and physical agents on living organisms with a multidisciplinary field of science concerned also known as ecotox or environmental toxicology

Related Societies and Associations  East Asian Union of Human Genetics Societies, Association of Chinese Geneticists in America, Hong Kong Society of Medical Genetics, Japan Society of Human Genetics, Genetics Society of Korea, Korean Society of Human Genetics,

Track 9:  Nutrition, Metabolism and Human Health.

Any biological specimen that is an indicator of nutritional status with respect to intake or metabolism of dietary constituents is termed as nutritional biomarkers. It can be a biochemical, functional or clinical index of status of an essential nutrient or other dietary constituent. Biomarkers as a means of validation of dietary instruments; surrogate indicators of dietary intake; or combined measures of nutritional status for a nutrient. For a biomarker to be used for validation of a dietary instrument, it should have a strong direct relationship with dietary intakes and be an independent assessment of the dietary intake of the nutrient of interest.

Related Societies and Associations: Genetics Society of Vietnam, Turkish Association of Medical Genetics, Japan Society of Gene Therapy, American Human Geneticists of Indian Subcontinent Origin

Track 10: Environmental indicator as biomarkers

To develop “early warning” indicators at the individual level that can predict population or ecosystem level impacts is the main aim of research of environmental biomarkers. The behavior (or activities) of an organism represent the final integrated result of a diversity of biochemical and physiological processes. Thus, a single evident parameter is generally more extensive than a physiological or biochemical parameter.

Related Societies and Associations: Association for International Cancer Research, Association of Oncology Social Work, Austrian Cancer Society, Bulgarian Cancer Association, Canadian Cancer Association, German Cancer Society, Italian Cancer Association,

Track 11: Future of biomarkers in assessment

The future application of biomarkers in critical illness will be to select and guide therapy. Selective biomarkers could analyze a pathophysiologic perturbation or noxious mediator to counteract or the need to replete a deficient protective protein. Functional genomics could identify patients at risk for illness or at risk for a poor outcome in critical illness. Genetic expression studies could help differentiate patients with the presence in tissues of harmful bacteria and their toxins from those with noninfectious inflammation and could also help to monitor illnesses over time. Expressional and functional proteomics could lead to the identification of new biomarkers and organ-specific therapies.

Related Societies and Associations: Japan Lung Cancer Society, National Cancer Institute of Argentina, American Society of Clinical Oncology, Asian Society of Neuro-Oncology, Association of Cancer Physicians, Association of Oncology Social Work, Belgian Association of Oncological Radiotherapy, Brain Tumor Foundation of Canada, Bolivian Society of Oncology

Track 12:  Genomics biomarkers

Current genomics and biotechnology promise the development of biomarkers to predict individual disease risk which enable early detection of disease, and improve diagnostic classification to better inform individualized treatment. Biomarkers are biological measurements that can be used to predict risk of disease, to enable early detection of disease, to improve treatment selection and to monitor the outcome of therapeutic interventions. The major objective of the Human Genome Project was the identification and development of such biomarkers for ‘personalized, preventive and predictive medicine.

Related Societies and Associations: Canadian Association of Pharmacy in Oncology, Cancer Association of Namibia, Cancer Association of South Africa, Canadian Association of Radiation Oncology, Cancer Research UK, Cancer Society of Nepal, Cancer Society of Brazil, Cancer Society of Finland, Cancer Society of New Zealand, American Association for Cancer Research, Association of Community Cancer Centers, Cancer Research Foundation

Track 13:  Genomics Medicine and Healthcare

An emerging medical discipline that involves using genomic information about an individual as part of their clinical care (e.g., for diagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use. Already, genomic medicine is making an impact in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious disease.

Related Societies and Associations: Cancer Council Austria, Dutch Cancer Society, Egyptian Cancer Society, Indonesian Society of Gynecologic Oncology, International Association of Cancer Registers, Jamaican Cancer Society, Jordon Cancer Society, Japanese Breast Cancer Society, Kidney Cancer Association, Korean Cancer Association, Lung Cancer Foundation of America, National Cancer Institute of Colombia

Track 14: Cardiovascular Genomics.

Cardiovascular disease (CVD) involving the heart, brain, and peripheral circulation is the leading cause of death worldwide. Genetics play a role in conferring risk for nearly all CVD disorders. Enormous effort has been undertaken to understand genes responsible for or protected from CVD. Cardiovascular disease encloses a range of conditions extending from myocardial infarction to congenital heart disease most of which are heritable. Immense effort has been invested in understanding the genes and specific DNA sequence variants responsible for this heritability.

Related Societies and Associations: National Cancer Registrars Association, National Health and Medical Research Council, Prostate Cancer Foundation, Prostate Cancer UK, Saudi Cancer Society, Saudi Oncology Society, Skin & Cancer Foundation Australia, Society for Neuro-Oncology, Spanish Association Against Cancer

 Track 15: Ecological Genomics

One of the major challenges in biology is to connect genotypes to phenotypes and to identify the ecological and demographic parameters that have shaped genotype frequencies in natural populations. Ecological Genomics is an integrative field of study that seeks to understand the genetic mechanisms underlying adaptive responses of organisms to their environment. Biological diversity emerges from the interaction between genomes and their environment. Recent conceptual and technological developments allow dissecting these interactions over short and long time-scales.

Related Societies and Associations: Swiss Cancer League, Uganda Child Cancer Foundation, Union for International Cancer Control, United Kingdom Association of Cancer Registries, Victorian Cancer Registry, World Federation of Surgical Oncology, World Health Organization- Africa Region, European Society for Medical Oncology, European Cancer organization, German Cancer Aid, Indian Cancer Society

Track 16: Human genomics

The entire set of nucleic acid sequence of an individual are being encoded as DNA within the 23 chromosome pairs in cell nuclei and in a small DNA molecule found within individual mitochondria is being an advancement in human genomics. Both protein-coding DNA genes and noncoding DNA are included in human genomics. Human Genomics focuses on the application of genomic analysis in all aspects of human health and disease, as well as the genomic analysis of adverse drug reactions, drug efficacy and safety.

Related Societies and Associations: Institute of Cancer of Sao Paulo, Israel Cancer Research Fund, Manchester Cancer Research Center, Peruvian Cancer Foundation, Swiss Cancer Center, Esophageal Cancer Awareness Association, Swedish Cancer Society, Spanish Oncology Nursing Society, Society for Immunotherapy of Cancer

Track 17: Future trend in genomics

Genomics research holds the key to meeting many of the challenges of the coming years. Now, the biggest challenge is in data analysis. We can generate large amounts of data very inexpensively, but that overwhelms our capacity to understand it. The major challenge of the Genome Research is we need to infuse genomic information into medical practice, which is hard. There are issues around confidentiality, education, electronic medical records, how to carry genomic information throughout lifespan and make it available to physicians.

Related Societies and Associations: American Brain Tumor Association, Association of Community Cancer Centers, Australian Cervical Cancer Foundation, Australian Prostate Cancer Research, Bermuda Cancer and Health Center, Bladder Cancer Canada, British Gynecological Cancer Society, Canadian Breast Cancer Research Alliance

Track 18: Next-Generation Sequencing for genomics Biomarkers

Next Generation Sequencing (NGS), massively parallel or deep sequencing are related terms that describe a DNA sequencing technology which has revolutionized genomic research. The global next Generation Sequencing market is poised to grow at a CAGR of more than 20% to reach around $5.0 billion by 2020. The NGS market assessment was made based on products, technologies, end users, applications and geography.

Related Societies and Associations: : Swiss Cancer League, Uganda Child Cancer Foundation, Union for International Cancer Control, United Kingdom Association of Cancer Registries, Victorian Cancer Registry, World Federation of Surgical Oncology, World Health Organization- Africa Region, European Society for Medical Oncology, European Cancer organization, German Cancer Aid, Indian Cancer Society



    Meetings International proudly announces the International Conference and Expo on Biomarkers and Genomic Medicine” which will be held during October:29-30, 2018 at Osaka, Japan. The theme of conference is Biomarkers: Inovation and Implementation of Genomics Research”. Meetings International provides a Global Platform for Medical, Healthcare Professionals Bioinformatics, Genomicist and Biotech Professionals to Exchange Ideas, Knowledge and Networking at its International Conferences.

Biomarkers meeting 2018 mainly focuses on Biomarkers and Genomics medicine, in the hands of clinical investigators, provide a dynamic and powerful approach to understanding the spectrum of diseases with obvious applications in oncology, epidemiology, biomarkers, genomics medicines and clinical research in disease prevention, diagnosis, and disease management. Cancer biomarkers and human genomics have the additional potential to identify individuals susceptible to disease. There is a good scope to know the latest approaches in the field of tools and technical sciences of biomarkers and their applications. In the recent years, the information about cancer biomarkers has increased providing good scope for improving the management of cancer patients by enhancing the accuracy of detection and efficacy of the treatment. Latest technological advancements have enabled the examination of many possible biomarkers and renewed interest in developing new biomarkers

 Why to attend???

With members from around the world focused on learning about Biomarkers and Genomics medicine and its advances; this is your best opportunity to reach the largest assemblage of participants from the Biomarkers and Genomics and its allied areas. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new Development of Biomarkers, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Biomarkers and Genomics medicine are hallmarks of this conference.

Target Audience: 

  • Biomarker and Genomics Research Students and Scientists
  • Biomarker and Genomics Researchers
  • Cancer and other Diseases Researchers
  • Medical Colleges & Pharmacology Professionals
  • Biomarker and genomics Associations and Societies
  • Genomicist, Bio pharmacists, Bio chemist and Biotech Professionals
  • Manufacturing Biomarkers Instruments Companies
  • Research and Diagnostic Laboratories and Companies
  • Data Management Companies
  • Pharmaceutical Companies
  • Business Entrepreneurs


International Conference and Expo on Biomarkers and Genomic Medicine is the best anticipated conference. It is the best way to collaborate with industry peers and discover knowledge and resources. This is the best opportunity to reach the largest assemblage of participants from the biomarkers and genomics community. This is the best platform for all the oncologists, scientists, students, research scholars who are well reputed in this field. This international event is the demand for new biomarkers in different applications has boosted the biomarkers market.

Meetings International warmly invites all the Eminent personalities, Reputed Scientists and Speakers, Industry Professionals, Healthcare and Academic Professionals from the Healthcare and Oncology field to share their thoughts and methodologies in this International event. This will bring a good result. It is open to all types of research methodologies both from academic and industry.


Biomarker technology is evidencing increased application from key segments such as disease diagnosis, drug development and formulation, diagnosis for exposure of certain harmful chemical and prognostic treatments. biomarkers are novel diagnostic solutions and advancement in it its development and understanding of human genome promotes its application in diagnosis of disease on molecular basis. Pharmaceutical companies which are interested in introducing novel diagnostic solution are increasing partnership and collaboration with private laboratories, educational institute and these companies are also increasing their investments in research and development.

The global market for diagnostic biomarker expected to reach about $30.6 billion in 2020 growing at CAGR of 16% from 2013 to 2020. Disease diagnostic application remains the key area of application that is expected to reach 6.1 $billion in 2020. However, application of diagnostic biomarkers in forensics and molecular diagnostics is catching up quite significantly. Molecular diagnostics is expected to grow at a CAGR of 17.6% from 2013 to 2020.




Global diagnostic Biomarker report segments the market in three categories; market by technologies, market by services, and market by diseases. These markets are expected to show elevated growth in future as biomarkers are providing diagnostic service for complex disease. As it is non-invasive procedure it motivates the use of biomarkers than conventional diagnostic applications. This report focuses on key factors impacting the diagnostic biomarker market used in risk assessment, molecular diagnostics, disease diagnosis, drug discovery and development, drug formulation, forensic applications and others. Diagnostic biomarker and its applications in emerging segments of omics, imaging technologies, personalized medicine, and bioinformatics are all discussed in detail.

Asia-Pacific biomarkers market is segmented based on the product, type, application, and disease indications. Based on product, the market is further sub-segmented as consumables, software, and services. Based on type, the market is segmented as safety biomarkers, efficacy biomarkers, and validation biomarkers. Biomarkers application is further segmented as diagnostics developments, drug discovery & developments, personalized medicine, and disease risk assessment. Based on disease indications, the market is segmented as cancer, cardiovascular, neurological, and immunological disorders.


Conference Highlights:

·         Biomarkers

·         Clinical application for biomarkers

·         Biomarkers in oncology

·         Biomarkers and Diseases

·         Biomarkers in diseases: methods discover and application

·         Development of Biomarkers

·         Imaging Biomarkers and Instrumentation.

·         Biomarkers in toxicology

·         Nutrition, Metabolism and Human Health.

·         Environmental indicator as biomarkers

·         Future of biomarkers in assessment

·         Genomics biomarkers

·         Genomics Medicine and Healthcare

·         Cardiovascular Genomics

·         Ecological Genomics

·         Human genomics

·         Future trend in genomics

·         Next-Generation Sequencing for genomics Biomarkers

Who to attend:

With individuals around the globe concentrated on finding out about Molecular, Genomics Medicine and Cancer Biomarkers; this is your best chance to achieve the biggest gathering of members from the Biomarkers and genomics medicine people group. Direct presentations, circulate data, meet with present and potential researchers, make a sprinkle with cutting edge medicines, and get name acknowledgment at this 2-day occasion. Widely acclaimed speakers, the latest procedures, advancements and the most current upgrades in Molecular, Genomics Medicine and Cancer Biomarkers are the signs of this gathering.

Why Japan:

The “Land of the Rising Sun” continues to be Asia’s number-one country in biotech and pharma patents (13,748 listing at least one Japanese inventor, according to WIPO), as well as a firm number-two in R&D ($170.082 billion in 2015, according to OECD). Japan is also second in jobs. However, Japan ranks lower in companies (third with 1,100+, including 591 biotech’s according to 2013 data released in 2015 by Japan Bioindustry Association), and fifth in IPOs, with two biopharma’s completing initial offerings totaling $38.5 million—the most recent being Solasia Pharma, which raised nearly ¥3.6 billion ($32 million) in March.
Based on geographical areas, Asia-Pacific biomarkers market is segmented as Japan, China, and India. Asia-Pacific biomarkers market is expected to reach USD 8.32 billion by 2020 from USD 3.93 billion in 2015, growing at a CAGR of 16.20% during forecast period 2015-2020. According to the market research analyst at Technavio, the regenerative medicine market in Japan will grow steadily and post a CAGR of approximately 35% by 2020. Sequencing and analyzing instruments accounted for over 40% of digital genome market share. Technological innovation for development of novel instruments coupled with growing investments in genetic research will provide thrust to industry expansion. Sequencing chips should witness over 10% CAGR owing to continuous R&D in bioinformatics, microfluidics, enzymology, and nanotechnology providing innovative platforms for digital genome market growth.

Top Market Players

·         Abbott Laboratories Inc.

·         Agilent Technologies Inc.

·         Aushon Biosystem

·         Bio-Red laboratories Eisai Co. Ltd

·         Epistem Ltd.

·         Ge HealthCare

·         Roche Diagnostics Limited

·         Siemens AG

·         Thermo Fisher Scientific Inc.

·         Dragon Genomics Center

·         Okinawa Institute of Science and Technology

·         RIKEN Genome Sciences Center

Major Associations around Japan:

·         Kyoto Pharmaceutical Association

·         Osaka Pharmaceutical Association

·         Wakayama Pharmaceutical Association

·         Tottori Pharmaceutical Association

·         Chubu Medical Devices Manufacturers Association


  • Biomarkers
  • Clinical application for biomarkers
  • Biomarker Discovery
  • Companion Diagnostics
  • Personalized Medicine
  • Biomarker in oncology
  • Molecular Biomarkers
  • Biomarkers and Drug Discovery
  • Biomarkers identification techniques
  • Case Reports
  • Biomarkers and Next-Generation Sequencing
  • Immunology Biomarkers
  • Precision medicine
  • Translational research/Sciences